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SUMMARY OF PROJECT  
 
Kinases WNK1-4 regulate cation-chloride cotransporters via phosphorylation of SPAK and OSR1 and thereby 
control salt homeostasis, cell volume and blood pressure. Gain of function mutations in WNK kinases are 
found in Gordon’s hypertension syndrome suggesting the WNK pathway as a therapeutic target. WNK3 
inhibition in particular has also been shown to reduce cerebral injury after Ischemic stroke. Here we present 
assays and crystal structures that define (i) the molecular basis for disease mutations; (ii) the multiple 
functional domains of WNK kinases and their protein interactions; (iii) the binding of small molecule kinase 
inhibitors and a potential allosteric pocket. 
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SCIENTIFIC BACKGROUND  
 
WNK1-4 (with no lysine) are chloride-sensing kinases with an atypical β2-strand catalytic lysine instead of 
β3. They phosphorylate kinases SPAK and OSR1 which in turn mediate regulatory phosphorylations on 
cation-chloride cotransporters (e.g. NKCC1, NKCC2, NCC)(Fig.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RFXV motifs in WNKs and co-transporters mediate interactions with Conserved C-Terminal (CCT) domains in 
SPAK, OSR1 and WNK1-4. WNKs can also dimerise through a coiled-coil domain and contain a degron motif 
for ubiquitin-dependent degradation by the E3 KLHL3/CUL3 (Fig. 2) 
 
  
Fig. 2. General domain organisation of WNK kinases. 
 
WNK1 and WNK4 are expressed in the kidney where they regulate salt homeostasis, cell volume and blood 
pressure. WNK isoforms including WNK3 are also expressed in the brain where their control of salt 
homeostasis regulates GABAergic signalling. 
Mutations in the degron motifs of WNK1 or WNK4 or the E3 ligase KLHL3-CUL3 block WNK degradation 
causing a gain of function in Gordon's Syndrome (also known as pseudohypoaldosteronism type II), a rare 
familial autosomal dominant disease leading to severe hypertension (1). Polymorphisms in WNK3 also link 
to hypertension in the Chinese population (2). 
Gain of function mutations in WNK kinases in hypertension suggest an application for WNK pathway 
inhibitors. Ischemia has also been shown to induce aberrant NKCC1 activation, cell death and cerebral injury 
after stroke. WNK3 knockout in mice reduced the associated brain damage and improved neurological 
recovery (3). 
 
 
RESULTS – THE TEP 
 
Proteins purified 
 
KLHL3 kelch domain (used for crystallography, assays) 
Human KLHL3 kelch domain (a.a. 298–587) was cloned into pNIC28-Bsa4, expressed in BL21(DE3)-R3-pRARE 
cells and purified using Ni-affinity, ion exchange and size exclusion chromatography. 
 
 
Fig.1. Schematic representation of 
WNK signalling and regulation by the 
ubiquitin-proteasome system (adapted 
from Am J Physiol Renal Physiol 
2016; 310(11), F1389-96.) 
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KLHL2 kelch domain (used for crystallography, assays) 
Human KLHL2 kelch domain (a.a. 294–593) was cloned into pNIC28-Bsa4, expressed in BL21(DE3)-R3-pRARE 
cells and purified using Ni-affinity, ion exchange and size exclusion chromatography. 
 
WNK3 kinase domain diphosphorylated (used for crystallography, assays) 
Human WNK3 kinase domain (a.a. 133-414) was cloned into pNIC28-Bsa4, expressed in BL21(DE3)-R3-pRARE 
cells and purified sequentially using Ni-affinity and size-exclusion chromatography. Bacterial expression 
yielded diphosphorylated WNK3 protein (Ser304 and Ser308). When desired the non-phosphorylated kinase 
domain was prepared by in vitro lambda phosphatase treatment or by bacterial coexpression with lambda 
phosphatase. 
 
WNK3 kinase domain monophosphorylated (used for crystallography, assays) 
Human WNK3 kinase domain (a.a. 132-414) was cloned into pFB-LIC-Bse and prepared by baculoviral 
expression. Predominantly Ser304 monophosphorylated WNK3 protein was purified sequentially using  
Ni-affinity and size-exclusion chromatography. 
 
WNK3 kinase-CCT1 domain fusion (used for crystallography, assays) 
Human WNK3 kinase and CCT1 domain (a.a. 123-500) were cloned into pFB-LIC-Bse and prepared by 
baculoviral expression. WNK3 protein was purified sequentially using Ni-affinity and size-exclusion 
chromatography. When required dephosphorylated WNK3 was prepared by co-infection of baculovirus 
expressing lambda phosphatase.   
 
WNK3 CCT1 domain (used for assays) 
Human WNK3 CCT1 domain (a.a. 406-500) was cloned into pNIC28-Bsa4, expressed in E. coli strain 
BL21(DE3)-R3-pRARE cells and purified sequentially using Ni-affinity and size-exclusion chromatography. 
 
WNK3 CCT2 domain (used for assays) 
Human WNK3 CCT2 domain (a.a. 741-820) was cloned into pNIC28-Bsa4, expressed in E. coli strain 
BL21(DE3)-R3-pRARE cells and purified sequentially using Ni-affinity and size-exclusion chromatography. 
 
WNK1 CCT1 domain (used for assays) 
Human WNK1 CCT1 domain (a.a. 480-572) was cloned into pNIC28-Bsa4, expressed in E. coli strain 
BL21(DE3)-R3-pRARE cells and purified sequentially using Ni-affinity and size-exclusion chromatography. 
 
WNK1 CCT2 domain (used for crystallography and assays) 
Human WNK1 CCT2 domain (a.a. 1115-1194) was cloned into pNIC28-Bsa4, expressed in E. coli strain 
BL21(DE3)-R3-pRARE cells and purified sequentially using Ni-affinity and size-exclusion chromatography. 
 
WNK4 CCT2 domain (used for assays) 
Human WNK4 CCT2 domain (a.a. 671-751) was cloned into pNIC28-Bsa4, expressed in E. coli strain 
BL21(DE3)-R3-pRARE cells and purified sequentially using Ni-affinity and size-exclusion chromatography. 
 
SPAK CCT domain (used for assays) 
Human SPAK CCT domain (a.a. 448-547) was cloned into pNIC28-Bsa4, expressed in E. coli strain  
BL21(DE3)-R3-pRARE cells and purified sequentially using Ni-affinity and size-exclusion chromatography. 
 
OSR1 CCT domain (used for assays) 
Human OSR1 CCT domain (a.a. 432-527) was cloned into pNIC28-Bsa4, expressed in E. coli strain  
BL21(DE3)-R3-pRARE cells and purified sequentially using Ni-affinity and size-exclusion chromatography. 
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Structural data  
 
1. WNK1 CCT2 domain (1.6 Å, PDB 5G3Q) 
2. WNK3 degron peptide + KLHL3 kelch domain (2.8 Å, PDB 5NKP) 
3. WNK4 degron peptide + KLHL2 kelch domain (1.6 Å, PDB 4CHB) 
4. WNK4 degron peptide + KLHL3 kelch domain (1.8 Å, PDB 4CH9) 
5. WNK3 kinase monophosphorylated apo (2.7 Å, PDB 5O23) 
6. WNK3 kinase A-loop exchange (1.7 Å, PDB 5O1V) 
7. WNK3 kinase + inhibitory Cl- ion (2.0 Å, PDB 5O21) 
8. WNK3 kinase diphosphorylated + AMP-PNP, (2.4 Å, PDB 5O26) 
9. WNK3 kinase + PP121 inhibitor (2.0 Å, PDB 5O2B) 
10. WNK3 kinase-CCT1 fusion (2.4 Å, PDB 5O2C) 
 
 
 
 
Structural rationale for Gordon’s syndrome mutations 
 
The WNK1-4 acidic degron motif binds to the KLHL2 and KLHL3 kelch domains in a manner distinct to the 
KEAP1 kelch domain consistent with their binding selectivity (Fig. 4). 
  
 
Fig. 4. Comparison of KLHL3-WNK4 and KEAP1-Nrf2 complexes 
 
Fig.3. Overview highlighting 
the diversity of WNK-family 
crystal structures determined 
in this study  
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Fig. 5. Structural basis for KLHL3 and WNK4 mutations in hypertension 
 
Analysis of the KLHL3-WNK4 interface shows that many of the disease-causing mutations inhibit binding by 
disrupting critical interface contacts (e.g. Fig. 5; KLHL3 R528H and WNK4 E562K). Others are predicted to 
have a negative impact on the overall tertiary structure and stability of the KLHL3 protein. Loss of WNK4 
binding to the KLHL3 E3 ligase prevents its ubiquitination and therefore results in WNK4 stabilisation and a 
gain of function. The structure of the more divergent WNK3 degron in complex with KLHL3 shows that all 
WNK isoforms bind similarly to KLHL2 and KLHL3 kelch domains. Further description of the interfaces can be 
found in Biochem J. (2014) 460, 237–246. 
 
Structural insights into the WNK3 kinase domain 
The apo and chloride-bound structures of the WNK3 kinase domain exhibit an inactive kinase conformation 
characterised by an αC-out conformation and an inhibitory αAL helix formed within the activation loop that 
supports the inhibitory function of chloride ions. By contrast, the inhibitory αAL helix was lost in WNK3 
complexes with AMP-PNP or the inhibitor PP121. Surprisingly, these complexes retained an αC-out 
conformation despite the presence of activation loop phosphorylation on WNK3 Ser304 and Ser308 (Fig. 6). 
This suggests that other as yet unknown factors may also regulate formation of the active WNK kinase 
conformation. 
 
 
Fig. 6. Kinase structural changes upon ligand binding 
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Structural insights into the CCT1 and CCT2 domains 
 
      
 
Interactions in the cascade between WNKs, SPAK/OSR1 and co-transporters are facilitated by RFXV peptide 
motif interactions with Conserved C-Terminal (CCT) domains in the kinases SPAK, OSR1 and WNK1-4. We 
determined the first structure of a WNK3 CCT1 domain attached to the kinase domain showing its proximity 
to the kinase active site (Fig. 3). We also prepared the first protein for the predicted WNK CCT2 regulatory 
domain and were able to solve the crystal structure of the WNK1 CCT2 domain (Fig. 7). This structure shows 
that the hypothetical CCT2 domain is indeed folded similarly to other known CCT domains. 
 
Structural insights into the binding of WNK3 kinase inhibitors 
The WNK3 kinase domain was solved in complex with the type I inhibitor PP121. The complex shows a  
DLG-in, αC-out conformation that creates an allosteric pocket that can be exploited for inhibitor 
development (Fig. 8).  Concurrently, with this work this concept was demonstrated independently by 
Novartis who published their inhibitor WNK463 bound to a similar pocket in WNK1 (PDB 5DRB; (4)).   
 
 
 
Fig. 8. PP121 inhibitor binding to WNK3 
 
 
In vitro assays 
 
1. Fluorescence polarisation assay for WNK degron binding to KLHL2/3 kelch domains 
2. Fluorescence polarisation assay for CCT domain-RFXV peptide interaction 
3. Thermal shift assay as an initial inhibitor binding screen 
4. In vitro kinase assays 
 
FP assay of WNK degron capture by KLHL3 
A fluorescence polarisation (FP) assay was used to measure the binding of WNK degron motif-containing 
peptides to the kelch domains of KLHL2 and KLHL3. Binding was in the low micromolar range for both KLHL2 
and KLHL3, except for WNK4 peptides containing disease-associated mutations which caused a dramatic 
reduction in binding (Fig. 9)(5). 
Fig.7. First structure of the hypothetical 
CCT2 domain highlighting its similarity to a 
OSR1 CCT domain-RFXV peptide 
complex. 
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Fig. 9. FP assay for WNK degron binding to KLHL3 
 
 
Inhibitor binding assays 
 
Prior to this study there was little evidence for WNK kinase inhibitors, except for one screen in 2009 
reporting WNK1 inhibition by Src-family inhibitors PP1 and PP2 (PP1 Ki  = 12.7 µM; (6)). We used a 
fluorescence-based thermal shift assay (differential scanning fluorimetry, DSF) to screen a collection of 860 
kinase inhibitors obtained from commercial vendors or GSK’s PKIS inhibitor set (7). Remarkably, only 3 
compounds produced a thermal shift of >3°C suggesting that the atypical β2 lysine in WNK kinases may 
interfere with the binding of many known traditional inhibitors (Fig. 11). The top hit (DTm > 5.7°C) was the 
inhibitor PP121 developed by Kevan Shokat (8). A radiolabelled in vitro kinase assay showed that PP121 
inhibited WNK1 and WNK3 with IC50 values of 160 nM and 215 nM, respectively. 
 
Chemical starting points 
 
Chemical matter with co-structures included AMP-PNP as well as PP121, which was developed as a dual 
inhibitor of tyrosine kinases and phosphatidylinositol-3-OH kinases (8).
 
Fig. 11. Identification of PP121 as a WNK3 inhibitor 
 
IMPORTANT: Please note that the existence of small molecules within this TEP indicates that chemical matter can bind to the protein 
in a functionally relevant pocket. As such these molecules should not be used as tools for functional studies of the protein unless 
otherwise stated as they are not sufficiently potent or well-characterised to be used in cellular studies. The small molecule ligands 
are intended to be used as the basis for future chemistry optimisation to increase potency and selectivity and yield a chemical probe 
or lead series. 
 
Antibodies 
 
The following sheep polyclonal antibody has proved effective: WNK3 1142-1461 [DU 4933; sheep S156C] 
available from MRC PPU Reagents and Services, University of Dundee. 
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CRISPR/Cas9 Reagents 
 
Reagents targeting human WNK3 have been published by others in Nat Biotech (2016) 34, 184–191 and are 
available from Addgene (plasmids #76925,  #76926,  #76927).  Alternatively, reagents are available from the 
human Dharmacon SMARTpool siRNA kinome library. 
 
Future questions 
 
• Further optimisation of chemical matter 
• Further exploration of WNK3 as a therapeutic target in hypertension and stroke 
• Further characterisation of WNK3 kinase activation 
 
Collaborations 
 
• WNK3 functional assays: Dario Alessi, MRC PPU, University of Dundee 
 
 
CONCLUSION  
 
WNK kinases control blood pressure and cell volume via their regulation of cation-chloride cotransporters. 
Genetic evidence supports their potential value as therapeutic targets in hypertension as well as for 
neuroprotection after stroke. We show that hypertension-associated mutations disrupt the recruitment of 
WNK kinases to the E3 ligases KLHL2 and KLHL3.  This TEP additionally provides a wealth of structural data 
to support further functional studies and inhibitor development, including the first structure of a WNK-CCT1 
domain construct and the first structure of the predicted CCT2 domain.  
 
PP121 was identified as one of the very few inhibitors apparently compatible with the atypical ATP-binding 
pocket of WNK3. The co-crystal structure of WNK3 and PP121 showed an inactive DLG-in, αC-out 
conformation of the kinase domain offering a potential allosteric pocket for inhibitor design.  Indeed, upon 
completion of this work, Novartis published the compound WNK463 as a pan-WNK kinase inhibitor 
exploiting this allosteric binding mode (4). 
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ADDITIONAL INFORMATION 
Structure Files 
PDB ID Structure Details 
5G3Q WNK1 CCT2 domain 
5NKP WNK3 degron peptide + KLHL3 kelch domain 
4CHB WNK4 degron peptide + KLHL2 kelch domain 
4CH9 WNK4 degron peptide + KLHL3 kelch domain 
5O23 WNK3 kinase monophosphorylated apo 
5O1V WNK3 kinase A-loop exchange 
5O21 WNK3 kinase + inhibitory Cl- ion 
5O26 WNK3 kinase diphosphorylated + AMP-PNP 
5O2B WNK3 kinase + PP121 inhibitor 
5O2C WNK3 kinase-CCT1 fusion 
 
Materials and Methods 
 
Assays 
 
Thermal Shift (DSF) Assay 
A fluorescence-based thermal shift assay (DSF) was performed as a screen to identify potential WNK3 
inhibitors. Ligands in this assay increase a protein’s melting temperature (Tm shift) by an amount proportional 
to their binding affinity. A solution of 1-2 µM WNK3-CCT1 protein in assay buffer (10 mM HEPES pH 7.5, 150 
mM NaCl) was mixed 1:1000 with SYPRO Orange (Invitrogen). Compounds to be tested were added to a final 
concentration of 12.5 µM. 20 µL of each sample were placed in a 96-well plate and heated from 25 to 95°C. 
Fluorescence was monitored using a Mx3005P real-time PCR instrument (Agilent) with excitation and emission 
filters set to 465 and 590 nm, respectively. Data were analysed with the MxPro software and curves fit in 
Microsoft Excel using the Boltzmann equation to determine the midpoint of thermal denaturation (Tm). 
Thermal shift values (DTm) induced by inhibitor binding were calculated relative to control wells containing 
protein and 2.5% DMSO. 
 
In vitro Kinase Assay 
General protocol: Test samples in 96 well plates are set up containing 0.5 µL inhibitor, 15 µL enzyme, 
substrate and buffer and incubated at room temperature for 5 min.  The assay is initiated by the addition of 
10 µL 33P Mg-ATP (at approximately Km for ATP) and incubated at room temperature for 30 min.  The assay 
is then stopped by the addition of orthophosphoric acid, harvested onto P81 filterplates, dried and read on a 
scintillation counter for 30 sec per well. The assays are published in Biochem J. (2003) 371, 199-204 and 
Biochem J (2007) 408, 297-315. 
WNK3  specific protocol: WNK3 (5-20 mU diluted in 20 mM MOPS pH 7, 1 mM EGTA, 0.01% Brij35, 5% glycerol, 
1 mg/mL BSA, 0.1% mercaptoethanol) is assayed against myelin basic protein, MBP, in a final volume of 25.5 
µL containing 8 mM MOPS pH 7, 0.02 mM EDTA, 5 mM MnCl2, 0.33 mg/mL MBP, 10 mM magnesium acetate 
and 0.005 mM [33P-γ-ATP] (50-1000 cpm/pmole) and incubated for 30 min at room temperature. Assays are 
stopped by addition of 5 µL of 0.5 M (3%) orthophosphoric acid and then harvested onto P81 Unifilter plates 
with a wash buffer of 50 mM orthophosphoric acid. 
 
Mass spectrometry 
Protein masses were determined using an Agilent LC/MSD TOF system with reversed-phase high-performance 
liquid chromatography coupled to electrospray ionization and an orthogonal time-of-flight mass analyser. 
Proteins were desalted prior to mass spectrometry by rapid elution off a C3 column with a gradient of 5-95% 
isopropanol in water with 0.1% formic acid. Spectra were analysed using the MassHunter software (Agilent). 
 
Fluorescence polarisation assay for WNK degron binding to KLHL2/3 kelch domains 
Fluorescence polarisation measurements were performed at 25°C with purified KLHL3 proteins in 50 mM  
Tris-HCl pH 7.5, 150 mM NaCl, 2 mM DTT.  All peptides contained an N-terminal linker required for conjugating 
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to the Lumio green flurophore (CCPGCCGGGG) and were initially resuspended in 50 mM ammonium 
biocarbonate pH 8. Peptide labelling was achieved by incubating 10 nM of each peptide in a 0.5 mL reaction 
mixture of 20 μM Lumio green in 50 mM TrisHCl pH 7.5, 150 mM NaCl, 2 mM DTT. Reactions were left to 
proceed in the dark for 2 h. The peptides were then dialysed for 16 h into 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 2 mM DTT using a Micro DispoDIALYZER with a 100 Da molecular weight cut off  (Harvard Apparatus).  
For fluorescence polarisation, mixtures were set up containing the indicated concentration of protein, 10 nM 
Lumio-green labelled peptide in a final volume of 30 µL. All individual bindings were performed in duplicate 
with at least 12 data points per curve. Fluorescence polarisation measures were made using a BMG PheraStar 
plate reader, with an excitation wavelength of 485 nm and an emission wavelength of 538 nm, and 
measurements were corrected to the fluorescent probe alone. Data analysis and graphing were then 
performed in GraphPad Prism; One Site Specific binding with Hill Slope was assumed (model Y=Bmax*X^h/Kd^h 
+ X^h) and the disassociation constant, and associated standard error were obtained. All experimental 
bindings were repeated a minimum of two times and comparable results were obtained.  
 
Protein Expression and Purification 
 
Human KLHL3 kelch domain 
Boundaries: residues 298–587 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
Human KLHL3 kelch domain was expressed from the vector pNIC28-Bsa4 in BL21(DE3)-R3-pRARE cells (a 
phage-resistant derivative of Rosetta2, Novagen).  Cultures (1 litre) in Terrific broth were incubated at 37°C 
until OD600 reached 2.0 and then cooled to 18°C and supplemented with 0.5 mM IPTG to induce protein 
expression overnight.  Cells were harvested by centrifugation, resuspended in binding buffer (50 mM HEPES 
pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol and 0.5 mM TCEP [tris-(2-carboxyethyl)phosphine] and 
lysed by sonication. The His6-tagged protein was purified using Ni2+-Sepharose resin (GE Healthcare) and 
eluted stepwise in binding 
buffer with 100-250 mM imidazole. Removal of the His6 tag was performed at 4°C overnight using TEV 
protease. KLHL3 was then further purified by anion exchange chromatography using a 5 mL HiTrap Q column 
(GE Healthcare) followed by a final buffer-exchange step into 50 mM HEPES pH 7.5, 300 mM NaCl, 5% glycerol 
and 0.5 mM TCEP using size-exclusion chromatography (Superdex 200 16/60, GE Healthcare). 
 
Human KLHL2 kelch domain 
Boundaries: residues 294–593 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
Human KLHL2 kelch domain was expressed from the vector pNIC28-Bsa4 in BL21(DE3)-R3-pRARE cells (a 
phage-resistant derivative of Rosetta2, Novagen).  Cultures (1 litre) in Terrific broth were incubated at 37°C 
until OD600 reached 2.0 and then cooled to 18°C and supplemented with 0.5 mM IPTG to induce protein 
expression overnight.  Cells were harvested by centrifugation, resuspended in binding buffer (50 mM HEPES 
pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol and 0.5 mM TCEP [tris-(2-carboxyethyl)phosphine] and 
lysed by sonication. The His6-tagged protein was purified using Ni2+-Sepharose resin (GE Healthcare) and 
eluted stepwise in binding 
buffer with 100-250 mM imidazole. Removal of the His6 tag was performed at 4°C overnight using TEV 
protease. KLHL2 was then further purified by cation exchange chromatography using a 5 mL HiTrap SP column 
(GE Healthcare) followed by a buffer-exchange step into 50 mM HEPES pH 7.5, 300 mM NaCl, 5% glycerol and 
0.5 mM TCEP using size-exclusion chromatography (Superdex 200 16/60, GE Healthcare). 
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Human WNK3 kinase domain (diphosphorylated) 
Boundaries: residues 133–414 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
Human WNK3 kinase domain was expressed from the vector pNIC28-Bsa4 in BL21(DE3)-R3-pRARE cells. 
Cultures were grown at 37°C in LB medium supplemented with 50 μg/mL kanamycin and 34 µg/mL 
chloramphenicol to an OD600 of 0.6, before expression at 18°C overnight and induction with 0.3 mM isopropyl 
1-thio-β-D-galactopyranoside (IPTG). Cells were then harvested by centrifugation at 5000g and resuspended 
in binding buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 5 mM imidazole, EDTA-free complete 
protease inhibitor cocktail (Roche)) and lysed by sonication.  Lysates were clarified by centrifugation in a JA 
25.50 rotor at 36000 g. His-tagged protein was immobilized on Ni2+-sepharose resin and bound proteins eluted 
using step gradients of Imidazole (50-250 mM). The eluted proteins were cleaved with TEV protease overnight 
at 4°C and further purified by size exclusion chromatography using an S200 HiLoad 16/60 Superdex column 
equilibrated in buffer containing 50 mM HEPES pH 7.5, 300 mM NaCl, and 0.5 mM TCEP. Proteins were 
concentrated using centrifugal ultrafiltration with a 10 kDa molecular weight cut-off point membrane. Protein 
purity of >95% was confirmed by SDS-PAGE and identity plus phosphorylation state verified by intact mass 
spectrometry. Bacterial expression yielded diphosphorylated WNK3 protein (Ser304 and Ser308). When 
desired the non-phosphorylated kinase domain was prepared by in vitro lambda phosphatase treatment or by 
bacterial coexpression with lambda phosphatase. 
 
Human WNK3 kinase domain (monophosphorylated) 
Boundaries: residues 132–414 
Vector: pFB-LIC-Bse 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: Sf9 insect cells 
 
Bacmid DNA was prepared from DH10Bac cells and used to transfect Sf9 insect cells for the preparation of 
initial baculovirus. WNK3 protein was expressed from infected Sf9 cells cultivated in InsectXpress medium 
(Lonza) for 48 hours at 27°C. Harvested cells were resuspended and purified similarly to the bacterially-
expressed WNK3 kinase domain described above. Baculoviral expression resulted in predominantly Ser304 
monophosphorylated WNK3 protein. 
 
Human WNK3 kinase-CCT1 domain fusion 
Boundaries: residues 123–500 
Vector: pFB-LIC-Bse 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: Sf9 insect cells 
 
Bacmid DNA was prepared from DH10Bac cells and used to transfect Sf9 insect cells for the preparation of 
initial baculovirus. WNK3 protein was expressed from infected Sf9 cells cultivated in InsectXpress medium 
(Lonza) for 48 hours at 27°C. Harvested cells were resuspended and purified similarly to the bacterially-
expressed WNK3 kinase domain described above. When required dephosphorylated WNK3 was prepared by 
co-infection of baculovirus expressing lambda phosphatase.   
 
Human WNK3 CCT1 domain 
Boundaries: residues 406–500 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
See general protocol for preparation of CCT domains below. 
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Human WNK3 CCT2 domain 
Boundaries: residues 741–820 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
See general protocol for preparation of CCT domains below. 
 
Human WNK1 CCT1 domain 
Boundaries: residues 480–572 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
See general protocol for preparation of CCT domains below. 
 
Human WNK1 CCT2 domain 
Boundaries: residues 1115–1194 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
See general protocol for preparation of CCT domains below. 
 
Human WNK4 CCT2 domain 
Boundaries: residues 671–751 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
See general protocol for preparation of CCT domains below. 
 
Human SPAK CCT domain 
Boundaries: residues 448–547 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
See general protocol for preparation of CCT domains below. 
 
Human OSR1 CCT domain 
Boundaries: residues 432–527 
Vector: pNIC28-Bsa4 
Tag and additions: TEV-cleavable N-terminal hexahistidine tag 
Expression cell: E. coli BL21(DE3)R3-pRARE2 
 
See general protocol for preparation of CCT domains below. 
 
General procedure for CCT domain preparation 
Human CCT domains were expressed from the vector pNIC28-Bsa4 in BL21(DE3)-R3-pRARE cells. Cultures were 
grown at 37°C in LB medium supplemented with 50 μg/mL kanamycin and 34 µg/mL chloramphenicol to an 
OD600 of 0.6, before expression at 18°C overnight and induction with 0.3 mM isopropyl 1-thio-β-D-
galactopyranoside (IPTG). Cells were then harvested by centrifugation at 5000g and resuspended in binding 
buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 5 mM imidazole, EDTA-free complete protease 
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inhibitor cocktail (Roche)) and lysed by sonication.  Lysates were clarified by centrifugation in a JA 25.50 rotor 
at 36000 g. His-tagged protein was immobilized on Ni2+-sepharose resin and bound proteins eluted using step 
gradients of Imidazole (50-250 mM). The eluted proteins were cleaved with TEV protease overnight at 4°C and 
further purified by size exclusion chromatography using an S75 HiLoad 16/60 Superdex column equilibrated in 
buffer containing 50 mM HEPES pH 7.5, 300 mM NaCl, and 0.5 mM TCEP. Proteins were concentrated using 
centrifugal ultrafiltration with a 3 kDa molecular weight cut-off point membrane. Protein purity of >95% was 
confirmed by SDS-PAGE and identity verified by intact mass spectrometry. Protein concentrations were 
determined by measuring absorbance at 280 nm, or in cases where extinction coefficients were too low, 
concentrations were determined using Bradford assays and validated with a Direct Detect Infrared 
Spectrometer. 
 
Structure Determination 
 
KLHL3/WNK4 complex (PDB: 4CH9) 
KLHL3 protein was concentrated to 9 mg/mL and mixed with 2 mM final concentration WNK4 peptide 
(EPEEPEADQHQ) for 30 minutes on ice. Crystallisation was performed using sitting-drop vapour-diffusion. 
Crystals of the KLHL3 complex were obtained at 20°C by mixing 100 nL of protein with 50 nL of a reservoir 
solution containing 0.1 M acetate pH 4.3, 0.2 M ammonium sulphate and 25-35 % PEG 4000. After 3 hours of 
incubation the drops were spiked with 20 nL of seed-stock solution. Prior to vitrification in liquid nitrogen, 
crystals were cryoprotected by direct addition of reservoir solution supplemented with 25 % ethylene glycol. 
Diffraction data were collected on beamline I02 at Diamond Light Source. Diffraction data were integrated 
using Mosflm and scaled using SCALA from the CCP4 software suite. Molecular replacement was performed 
with Phaser MR in CCP4 using PDB ID code 2XN4 chain A (apo kelch domain of KLHL2) as the search model. 
COOT was used for manual model building and refinement, while REFMAC and PHENIX.REFINE were used for 
automated refinement. TLS parameters were included at later stages of refinement. Tools in COOT, PHENIX 
and MolProbity were used to validate the structures. 
 
KLHL2/WNK4 complex (PDB: 4CHB) 
KLHL2 protein was concentrated to 9 mg/mL and mixed with 2 mM final concentration WNK4 peptide 
(EPEEPEADQHQ). The protein-peptide solution was incubated on ice for approximately 30 minutes prior to 
preparation of sitting-drop vapour-diffusion crystallisation plates. Diffracting crystals were obtained at 20°C 
by mixing 100 nL of protein with 50 nL of a reservoir solution containing 0.1 M HEPES pH 7.2, 2.5 M ammonium 
sulphate and 2 % PEG 400. After 3 hours of incubation the drops were spiked with 20 nL of seed-stock solution. 
Prior to vitrification in liquid nitrogen, crystals were cryoprotected by direct addition of reservoir solution 
supplemented with 25 % ethylene glycol. Diffraction data were collected on beamline I02 at Diamond Light 
Source. Diffraction data were integrated using Mosflm and scaled using SCALA from the CCP4 software suite. 
Molecular replacement was performed with Phaser MR in CCP4 using PDB ID code 2XN4 chain A (apo kelch 
domain of KLHL2) as the search model. COOT was used for manual model building and refinement, while 
REFMAC and PHENIX.REFINE were used for automated refinement. TLS parameters were included at later 
stages of refinement. Tools in COOT, PHENIX and MolProbity were used to validate the structures. 
 
KLHL3/WNK3 complex (PDB: 5NKP) 
KLHL3 was concentrated to 9 mg/mL buffered in 50 mM HEPES pH 7.5, 300 mM NaCl, 0.5 mM TCEP, 2 mM 
DTT and mixed with 2 mM WNK3 acidic motif peptide (ECEETEVDQHV). Diffracting crystals were obtained at 
4°C in sitting drops by mixing 100 nL protein with 50 nL solution containing 6% PEG4K, 0.1 M acetate pH 5.1. 
After 3 hours of incubation the drops were spiked with 20 nL of seed-stock solution. Prior to vitrification in 
liquid nitrogen, crystals were cryoprotected by direct addition of reservoir solution supplemented with 25 % 
ethylene glycol. Diffraction data were collected on beamline I03 at Diamond Light Source. Diffraction data 
were processed using PHENIX. Molecular replacement was performed with Phaser MR in Phenix using PDB 
4CH9 as the model. COOT was used for manual model building and refinement, whereas PHENIX.REFINE was 
used for automated refinement. TLS parameters were included at later stages of refinement. 
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General methods for structure determination of WNK kinase and CCT domains 
Data were indexed and integrated using XDS and scaled using AIMLESS in the CCP4 suite of programs. Phases 
were found using molecular replacement in PHASER. Models were built initially using COOT and then refined 
and modified using alternate rounds of REFMAC5 and COOT. Specific details for each structure are listed 
below. 
 
WNK3 kinase-CCT1 (dephosphorylated) 
Dephosphorylated WNK3 Kinase-CCT1 (a.a. 123-500) was buffered in 50 mM HEPES pH 7.5, 300 mM NaCl, 5% 
glycerol, 0.5 mM TCEP, and concentrated to 9.6 mg/mL. Crystals were grown at 4°C in 400 nL sitting drops at 
a 1:1 protein: reservoir solution comprising 18% PEG3350, 0.1 M citrate pH 5. Before mounting, crystals were 
cryo-protected with mother liquor supplemented with an additional 25 % glycerol and vitrified in liquid 
nitrogen. Diffraction data were collected at Diamond Light Source beamline I03. 
 
WNK3 kinase domain (apo, monophosphorylated) 
Monophosphorylated WNK3 kinase domain (a.a. 132-414) was buffered in 50 mM HEPES pH 7.5, 300 mM 
NaCl, 0.5 mM TCEP, and concentrated to 12.3 mg/mL. Crystals were grown at 20°C in 150 nL sitting drops at a 
1:1 protein: reservoir solution comprising 30% PEG Smear Medium, 0.2 M lithium sulfate, 0.1 M ADA pH 6.5. 
Before mounting, crystals were cryo-protected with mother liquor supplemented with an additional 25% 
ethylene glycol and vitrified in liquid nitrogen. Diffraction data were collected at Diamond Light Source 
beamline I03. 
 
WNK3 kinase (Cl- bound, monophosphorylated) 
Monophosphorylated WNK3 kinase domain (a.a. 132-414)  was buffered in 50 mM HEPES pH 7.5, 300 mM 
NaCl, 0.5 mM TCEP, and concentrated to 10 mg/mL. 1 mM adenosine diphosphate (ADP) and 2 mM MgCl2 
were added, but not observed in the resulting structure. Crystals were grown at 4°C in 150 nL sitting drops at 
a 2:1 protein: reservoir solution comprising 22.5% PEG Smear Broad, 0.1 M sodium/potassium tartrate, 10% 
ethylene glycol, 0.1 M cacodylate pH 5.5. Before mounting, crystals were cryo-protected with mother liquor 
supplemented with an additional 25 % ethylene glycol and vitrified in liquid nitrogen. Anomalous data with 
high redundancy were collected at Diamond Light Source beamline I04 using a wavelength of 1.77Å. 
 
WNK3 kinase (monophosphorylated,  A-loop exchange) 
Monophosphorylated WNK3 kinase domain (a.a. 132-414) was buffered in 50 mM HEPES pH 7.5, 300 mM 
NaCl, 0.5 mM TCEP, and concentrated to 10 mg/mL. 1 mM adenylyl-imidodiphosphate (AMP-PNP) and 2 mM 
MgCl2 were added, but not observed in the resulting structure. Crystals were grown at 4°C in 150 nL sitting 
drops at a 2:1 protein: reservoir solution comprising 20% PEG4000, 10% 2-propanol, 0.1M HEPES pH 7.5. 
Before mounting, crystals were cryo-protected with mother liquor supplemented with an additional 25 % 
ethylene glycol and vitrified in liquid nitrogen. Diffraction data were collected at Diamond Light Source 
beamline I04. 
 
WNK3 kinase (AMP-PNP bound, diphosphorylated) 
Diphosphorylated WNK3 kinase domain (a.a 133-414) was buffered in 50 mM HEPES pH 7.5, 50 mM NaCl, 
0.5 mM TCEP, 10 mM DTT and concentrated to 9.5 mg/mL. A final concentration of 4 mM adenylyl-
imidodiphosphate (AMP-PNP) and 10 mM MgCl2 were added. Crystals were grown at 20°C in 150 nL sitting 
drops at a 1:2 protein: reservoir solution comprising 25% PEG3350, 0.1M bis-tris pH 5.5. Before mounting, 
crystals were cryo-protected with mother liquor supplemented with an additional 25 % ethylene glycol and 
vitrified in liquid nitrogen. Diffraction data were collected at Diamond Light Source beamline I04. 
 
WNK3 kinase (PP121 bound, diphosphorylated) 
Diphosphorylated WNK3 kinase domain (a.a 133-414) was buffered in 50 mM HEPES, 50 mM NaCl, 1 mM TCEP 
and concentrated to 9 mg/mL. A final concentration of 1 mM PP121 was added. Crystals were grown at 20°C 
in 150 nL sitting drops at a 1:1 protein: reservoir solution comprising 25% PEG3350, 0.2M magnesium chloride, 
0.1M bis-tris pH 5.5. Before mounting, crystals were cryo-protected with mother liquor supplemented with an 
additional 25 % ethylene glycol and vitrified in liquid nitrogen. Diffraction data were collected at Diamond 
Light Source beamline I04. 
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WNK1 CCT2 domain 
WNK1 CCT2 domain (a.a 1115-1201) was buffered in 20 mM HEPES, 100 mM NaCl and concentrated to 12 
mg/mL. Crystals were grown at 20°C in 150 nL sitting drops at a 1:1 protein: reservoir solution comprising 
25% PEG3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5. Before mounting, crystals were cryo-
protected with mother liquor supplemented with an additional 25 % ethylene glycol and vitrified in liquid 
nitrogen. Diffraction data were collected at Diamond Light Source beamline I04-1. 
 
References 
 
1. Alessi, D. R., Zhang, J., Khanna, A., Hochdorfer, T., Shang, Y., and Kahle, K. T. (2014) The WNK-SPAK/OSR1 
pathway: master regulator of cation-chloride cotransporters. Science signaling 7, re3 
2. Wu, S., Niu, W., Zhang, Y., Gao, P., and Zhu, D. Gender-specific association between polymorphisms in the 
WNK3 gene and essential hypertension in a Chinese population. International Journal of Cardiology 137, 
S111 
3. Begum, G., Yuan, H., Kahle, K. T., Li, L., Wang, S., Shi, Y., Shmukler, B. E., Yang, S. S., Lin, S. H., Alper, S. L., 
and Sun, D. (2015) Inhibition of WNK3 Kinase Signaling Reduces Brain Damage and Accelerates Neurological 
Recovery After Stroke. Stroke 46, 1956-1965 
4. Yamada, K., Park, H. M., Rigel, D. F., DiPetrillo, K., Whalen, E. J., Anisowicz, A., Beil, M., Berstler, J., 
Brocklehurst, C. E., Burdick, D. A., Caplan, S. L., Capparelli, M. P., Chen, G., Chen, W., Dale, B., Deng, L., Fu, F., 
Hamamatsu, N., Harasaki, K., Herr, T., Hoffmann, P., Hu, Q. Y., Huang, W. J., Idamakanti, N., Imase, H., Iwaki, 
Y., Jain, M., Jeyaseelan, J., Kato, M., Kaushik, V. K., Kohls, D., Kunjathoor, V., LaSala, D., Lee, J., Liu, J., Luo, Y., 
Ma, F., Mo, R., Mowbray, S., Mogi, M., Ossola, F., Pandey, P., Patel, S. J., Raghavan, S., Salem, B., Shanado, Y. 
H., Trakshel, G. M., Turner, G., Wakai, H., Wang, C., Weldon, S., Wielicki, J. B., Xie, X., Xu, L., Yagi, Y. I., 
Yasoshima, K., Yin, J., Yowe, D., Zhang, J. H., Zheng, G., and Monovich, L. (2016) Small-molecule WNK 
inhibition regulates cardiovascular and renal function. Nature chemical biology 12, 896-898 
5. Schumacher, F. R., Sorrell, F. J., Alessi, D. R., Bullock, A. N., and Kurz, T. (2014) Structural and biochemical 
characterization of the KLHL3-WNK kinase interaction important in blood pressure regulation. The 
Biochemical journal 460, 237-246 
6. Yagi, Y. I., Abe, K., Ikebukuro, K., and Sode, K. (2009) Kinetic mechanism and inhibitor characterization of 
WNK1 kinase. Biochemistry 48, 10255-10266 
7. Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., 
Huang, X.-P., Roth, B. L., Al Haj Zen, A., Fourches, D., Muratov, E., Tropsha, A., Morris, J., Teicher, B. A., 
Kunkel, M., Polley, E., Lackey, K. E., Atkinson, F. L., Overington, J. P., Bamborough, P., Müller, S., Price, D. J., 
Willson, T. M., Drewry, D. H., Knapp, S., and Zuercher, W. J. (2015) Comprehensive characterization of the 
Published Kinase Inhibitor Set. Nature Biotechnology 34, 95 
8. Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., 
Shokat, K. M., and Knight, Z. A. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine 
and phosphoinositide kinases. Nature chemical biology 4, 691-699 
We respectfully request that this document is cited using the DOI value as given above if the content is 
used in your work.  
 
